Print Get Citation Citation Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy. AMA Citation Lennon J, Chan A. Lennon J, & Chan A Lennon, Jack, and Alex Chan. Association of intensive blood pressure control with magnetic resonance imaging biomarkers of Alzheimer’s Disease. 2 Minute Medicine, 22 March 2021. McGraw-Hill, 2021. AccessCardiology. https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=555825§ionid=254721019APA Citation Lennon J, Chan A. Lennon J, & Chan A Lennon, Jack, and Alex Chan. (2021). Association of intensive blood pressure control with magnetic resonance imaging biomarkers of alzheimer’s disease. (2021). 2 minute medicine. McGraw-Hill. https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=555825§ionid=254721019.MLA Citation Lennon J, Chan A. Lennon J, & Chan A Lennon, Jack, and Alex Chan. "Association of intensive blood pressure control with magnetic resonance imaging biomarkers of Alzheimer’s Disease." 2 Minute Medicine McGraw-Hill, 2021, https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=555825§ionid=254721019. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content Association of intensive blood pressure control with magnetic resonance imaging biomarkers of Alzheimer’s Disease by Jack Lennon, Alex Chan Listen +Originally published by 2 Minute Medicine® (view original article). Reused on AccessMedicine with permission. +1. Intensive treatment of blood pressure resulted in small but statistically significant greater decline in hippocampal volume compared to standard treatment. +2. No significant differences between treatment groups in other Alzheimer’s disease biomarkers. +Evidence Rating Level: 2 (Good) +Several randomized clinical trials have suggested that control of hypertension reduces future risk of cognitive impairment and dementia. However, meta-analyses of these trials have not demonstrated how Alzheimer’s disease (AD) pathology is affected by the treatment of hypertension. This secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT MIND) randomized trial aimed to investigate the association of intensive blood pressure control on AD biomarkers, such as hippocampal volume, regional atrophy, posterior cerebral blood flow, and mean fractional anisotropy in the cingulum bundle. Participants were 50 years of age or older with documented hypertension and without a history of stroke or diabetes. A total of 673 participants had baseline MRI (M [SD] age = 67.3 [8.2] years, 40.3% female) and 454 completed the follow-up MRI (median (IQR) time = 3.98 [3.7 to 4.1] years) after randomization to either a systolic blood pressure goal of ≥120 mm Hg (intensive treatment, n = 356) or ≤140 mm Hg (standard treatment, n = 317). The intensive treatment group demonstrated small but statistically significant greater decrease in hippocampal volume (difference -0.06cm3, 95% CI -0.08 to -0.04) compared to the standard treatment group (difference, -0.02cm3, 95% CI -0.05 to -0.003, p = 0.03). Interestingly, no significant differences were found between treatment groups in measures of cerebral blood flow, AD regional atrophy, or mean fractional anisotropy. Overall, this study suggests that intensive control of blood pressure results in greater reductions of hippocampal volume and, thus, total brain volume, compared to standard treatment. However, these differences were small and not found in the context of other AD biomarkers. +Click to read the study in JAMA Neurology +©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.